The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma
Official Title: Consolidation Therapy With Bortezomib <= 60 Year Old Patients With Multiple Myeloma
Study ID: NCT00416273
Brief Summary: The purpose of this study is determination of the event-free survival with and without Bortezomib consolidation therapy from the day of the first chemotherapeutic, myeloma-specific therapy measure, up to the occurrence of progression/recurrence or up to the occurrence of death.
Detailed Description: This is a two-arm (group), open-label (all people know the identity of the intervention), prospective (a study in which the patients are identified and then followed forward in time for the outcome of the study) randomized (the study medication is assigned by chance), multi-center study. Approximately 385 patients will be enrolled in this study. Patients will be randomly assigned to treatment or observation group in a ratio of 1:1. The study duration from screening up to the study end is up to 27 weeks. Then the patients will be observed until the last included patient has completed a 30 month post observational phase. The patients in the treatment arm will receive 4 cycles of a therapy. Each cycle lasts for a 35 days. Safety evaluations will include assessment of adverse events, vital signs, physical examination, electrocardiograms, and clinical laboratory tests.
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
, Augsburg, , Germany
, Bamberg, , Germany
, Berg, , Germany
, Berlin, , Germany
, Bremen, , Germany
, Dresden, , Germany
, Duisburg, , Germany
, Erlangen, , Germany
, Eschweiler, , Germany
, Frankfurt / Main, , Germany
, Freiburg, , Germany
, Goch, , Germany
, Greifswald, , Germany
, Göttingen, , Germany
, Halle, , Germany
, Hamburg, , Germany
, Hamm, , Germany
, Hannover, , Germany
, Homburg, , Germany
, Jena, , Germany
, Karlsruhe, , Germany
, Kempten, , Germany
, Kiel, , Germany
, Köln, , Germany
, Magdeburg, , Germany
, Mainz, , Germany
, Mutlangen, , Germany
, München, , Germany
, Münster, , Germany
, Nürnberg, , Germany
, Oldenburg, , Germany
, Regensburg, , Germany
, Rostock, , Germany
, Stuttgart, , Germany
, Ulm, , Germany
, Villingen-Schwenningen, , Germany
, Wiesbaden, , Germany
, Würzburg, , Germany
Name: Janssen-Cilag G.m.b.H, Germany Clinical Trial
Affiliation: Janssen-Cilag G.m.b.H
Role: STUDY_DIRECTOR